Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-15
2009-02-24
Saeed, Kamal A (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S400000, C548S416000, C548S427000, C548S429000, C548S430000, C548S452000, C548S454000, C548S468000, C546S026000, C546S079000, C546S080000, C546S081000, C546S084000, C549S013000, C549S023000, C549S026000, C549S200000, C549S356000, C549S381000, C549S385000, C549S387000, C514S188000, C514S277000, C514S315000, C514S319000, C514S320000, C514S321000, C514S322000, C514S359000, C514S408000, C514S430000, C514S432000, C514S444000, C514S449000, C514S451000, C514S453000, C514S454000
Reexamination Certificate
active
07495111
ABSTRACT:
3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1Areceptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
REFERENCES:
patent: 4624954 (1986-11-01), Jirkovsky et al.
patent: 4665183 (1987-05-01), Jirkovsky et al.
patent: 4904658 (1990-02-01), Tseng et al.
patent: 5219857 (1993-06-01), Tseng et al.
patent: 5288748 (1994-02-01), Wikstrom et al.
patent: 6084130 (2000-07-01), Romero et al.
patent: 6127357 (2000-10-01), Cliffe et al.
patent: 6465482 (2002-10-01), Mewshaw et al.
patent: 6469007 (2002-10-01), Childers et al.
patent: 6586436 (2003-07-01), Childers et al.
patent: 6825212 (2004-11-01), Bernotas et al.
patent: 6995176 (2006-02-01), Bernotas et al.
patent: 7041695 (2006-05-01), Cole
patent: 2005/0032873 (2005-02-01), Hatzenbuhler et al.
patent: WO-97/03982 (1997-02-01), None
patent: WO-02/088132 (2002-11-01), None
patent: WO-02/088145 (2002-11-01), None
patent: WO-03/010169 (2003-02-01), None
patent: WO-03/087086 (2003-10-01), None
patent: WO-2004/024731 (2004-03-01), None
patent: WO-2004/099214 (2004-11-01), None
Araneda, et al., “5-Hydroxytryptamine2and 5-Hydroxytryptamine1AReceptors Mediate Opposing Responses on Membrane Excitability in Rat Association Cortex”, Neuroscience, 40(2):399-412 (1991).
Artigas, et al., “Acceleration of the Effect of Selected Antidepressant Drugs in Major Depression by 5-HT1AAntagonists”, Trends Neurosci., 19(9):378-383 (1996).
Balducci, et al., “Reversal of Visual Attention Dysfunction after AMPA Lesions of the Nucleus Basalis Magnocellularis (NBM) by the Cholinesterase Inhibitor Donepezil and by a 5-HT1AReceptor Antagonist WAY 100635”, Psychopharmacology, 167:28-36 (2003).
Blier, et al., “Effectiveness of Pindolol with Selected Antidepressant Drugs in the Treatment of Major Depression”, J. Clin. Psychopharmacol., 15(3):217-222 (1995).
Blier, et al., “Modifications of the Serotonin System by Antidepressant Treatments: Implications for the Therapeutic Response in Major Depression”, Journal of Clinical Psychopharmacology, 7(6 Suppl):24S-35S (1987).
Boast, et al., “5HT Antagonists Attenuate MK801-Impaired Radial Arm Maze Performance in Rats”, Neurobiology of Learning and Memory, 71:259-271 (1999).
Bowen, et al., “Neurotransmission—the Link Integrating Alzheimer Research?”, Trends in Neurosciences, 17(4):149-150 (1994).
Carli, et al., “WAY 100635, a 5-HT1AReceptor Antagonist, Prevents the Impairment of Spatial Learning Caused by Blockade of Hippocampal NMDA Receptors”, Neuropharmacology, 38:1165-1173 (1999).
Carli, et al., “WAY 100635, a 5-HT1AReceptor Antagonist, Prevents the Impairment of Spatial Learning Caused by Intrahippocampal Administration of Scopolamine or 7-Chloro-Kynurenic Acid”, Brain Research, 774:167-174 (1997).
Carli, et al., “(S)-WAY 100135, a 5-HT1AReceptor Antagonist, Prevents the Impairment of Spatial Learning Caused by Intrahippocampal Scopolamine”, European Journal of Pharamcology, 283:133-139 (1995).
Childers, et al., “Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT1AAntagonists: The Discovery of Lecozotan”, J. Med. Chem., 48:3467-3470 (2005).
Dijk, et al., “NMDA-Induced Glutamate and Aspartate Release from Rat Cortical Pyramidal Neurones: Evidence for Modulation By a 5-HT1AAntagonist”, British Journal of Pharmacology, 115:1169-1174 (1995).
Dimitriou, “Buspirone Augmentation of Antidepressant Therapy”, J. Clinical Psychopharmacol., 18(6):465-469 (1998).
Driver, et al., “A Second-Generation Catalyst for Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdCl2”, J. Am. Chem. Soc., 118:7217-7218 (1996).
Dunlop, et al., “Characterization of 5-HT1AReceptor Functional Coupling in Cells Expressing the Human 5-HT1AReceptor as Assesed with the Cytosensor Microphysiometer”, Journal of Pharmacological and Toxicological Methods, 40:47-55 (1998).
Feiger, “A Double-Blind Comparison of Gepirone Extended Release, Imipramine, and Placebo in the Treatment of Outpatient Major Depression”, Psychopharmacol. Bull., 32(4):659-665 (1996).
Grof, et al., “An Open Study of Oral Flesinoxan, a 5-HT1AReceptor Agonist, in Treatment-Resistant Depression”, International Clinical Psychopharmacology, 8:167-172 (1993).
Harder, et al., “The 5-HT1AAntagonist, WAY 100 635, Alleviates Cognitive Impairments Induced by Dizocilpine (MK-801) in Monkeys”, Neuropharmacology, 39:547-552 (2000).
Harder, et al., “The 5-HT1AAntagonist, WAY 100635, Ameliorates the Cognitive Impairment Induced by Fornix Transection in the Marmoset”, Psychopharmacology, 127:245-254 (1996).
Hume, et al., “Evaluation of [O-methyl-3H]WAY-100635 as an in vivo Radioligand for 5-HT1AReceptors in Rat Brain”, European Journal of Pharmacology, 271:515-523 (1994).
Jones, “Synthesis of the Quinoline Ring System”, Heterocylcic Compounds: vol. 32 (Quinolines),Chapter 2, Interscience, New York, pp. 93-318 (1977).
Matsuyama, et al., “Regulation of Glutamate Release via NMDA and 5-HT1AReceptors in Guinea Pig Dentate Gyrus”, Brain Research, 728:175-180 (1996).
McLoughlin, et al., “Central Serotonergic Hyperresponsivity in Late-Onset Alzheimer's Disease”, American Journal of Psychiatry, 151(11):1701-1703 (1994).
Perez, et al., “Randomised, Double-Blind, Placebo-Controlled Trial in Pindolol in Combination with Fluoxetine Antidepressant Treatment”, The Lancet, 349:1594-1597 (1997).
Rabiner, et al., “5-Hydroxytryptamine1AReceptor Occupancy by Novel Full Antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A[11C][Omethyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinlyethyl)-N-(2-pyridinyl)cyclohexanecarboxamide Trihydrochloride (WAY-100635) Positron Emission Tomography Study in Humans”, Journal of Pharmacology and Experimental Therapeutics, 301(3):1144-1150 (2002).
Sakai, et al., “Inhibitory Modulation of Long-Term Potentiation via the 5-HT1AReceptor in Slices of the Rat Hippocaompal Dentate Gyrus”, Brain Research, 613:326-330 (1993).
Schechter, et al., “Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties”, Journal of Pharmacology and Experimental Therapeutics, 314(3):1274-1289 (2005).
Tome, et al., “Serotonergic Autoreceptor Blockade in the Reduction of Antidepressant Latency: Personality Variables and Response to Paroxetine and Pindolol”, J. Affect Disord., 44:101-109 (1997).
Wilcox, et al., “A Double-Blind Trial of Low- and High-Dose Ranges of Gepirone-ER Compared with Placebo in the Treatment of Depressed Outpatients”, Psychopharmacol. Bull., 32(3):335-342 (1996).
Wolfe, et al., “An Improved Catalyst System for Aromatic Carbon—Nitrogen Bond Formation: The Possible Involvement of Bis(Phosphine) Palladium Complexes as Key Intermediates”, J. Am Chem. Soc., 118:7215-7216 (1996).
Yasuno, et al., “Inhibitory Effect of Hippocampal 5-HT1AReceptors on Human Explicit Memory”, American Journal of Psychiatry, 160(2):334-340 (2003).
Yuen, et al., “Serotonin 5-HT1AReceptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism”, Journal of Neuroscience, 25(23):5488-5501 (2005).
Yoo, et al., “Synthesis of Heteroarylpiperazines and Heteroary
Harrison Boyd L.
Ramamoorthy P. Sivaramakrishnan
Shen Zhongqi
Saeed Kamal A
Shterengarts Samantha L
Wilmer Cutler Pickering Hale and Dorr LLP
Wyeth
LandOfFree
Compounds useful as serotonin inhibitors and 5-HT 1A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds useful as serotonin inhibitors and 5-HT 1A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful as serotonin inhibitors and 5-HT 1A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4092752